The field of diabetes treatment continues to experience a surge in innovation with the emergence of novel GLP-1 receptor agonists. Among these, retatrutide and trizepatide are rapidly emerging as potential https://zoeoutw724134.dsiblogger.com/71952302/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide